EUCTR2021-001663-24-ES进行中（未招募）1 期
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19 - Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 820
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Clinical risk based on age = 55 years or an adult (age = 18 years) with an immunosuppressed condition.
- •2. Positive test for SARS-CoV-2 within =5 days (if >1 test, the first positive is within =5 days). Tests may include an institutional-based nucleic acid amplification test (NAAT), or any protocol-approved rapid test.
- •3. Within =5 days from symptom onset, if symptomatic from current SARS-CoV-2 infection.
- •4. Agrees to not participate in another clinical trial for the treatment or management of SARS-CoV-2 infection through Day 7, or until hospitalized or significant disease progression if prior to Day 7 (defined by ordinal category 4 or 5).
- •5. Participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through Day 28.
- •Information on which patient populations may benefit most from passive immune strategies targeting SARS-CoV-2 are limited. However, patients with impaired immune responses, whether from an underlying condition or the result of medical treatments, may have a delayed and/or reduced endogenous antibody response during COVID-19.
- •Ongoing immunosuppressive condition or immunosuppressive treatment, includes:
- •Steroids equivalent to prednisone > 10 mg/day for at least the last 28 days
- •Rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy
- •Antirejection medicine after solid organ or stem cell transplantation
- •Cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months
- •Primary or acquired severe B- or T-lymphocyte immune dysfunction
- •HIV infection
- •Splenectomy or functional asplenia
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 600
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •1. Asymptomatic and had prior symptoms from the current infection that have now resolved (for >24 hours).
- •2. Asymptomatic and has received a vaccination for COVID-19 (=1 dose).
- •3. Undergoing evaluation for possible admission to hospital for medical management (this does not include evaluation of possible hospitalization for public health purposes).
- •4. Evidence of pneumonia and/or hypoxia due to COVID-19 (NOTE: chest imaging is not required, but if available it should not show new infiltrates suggestive of pneumonia; hypoxia is defined by new oxygen supplementation or increase above pre-illness level).
- •5. Prior receipt of immunoglobulin product or passive immune therapy for SARS-CoV-2 in the past 90 days (i.e., convalescent plasma, SARS-CoV-2 monoclonal antibodies, or any IVIG).
- •6. Any of the following thrombotic or procoagulant conditions or disorders:
- •acute coronary syndrome, cerebrovascular syndrome, pulmonary embolism, or deep venous thrombosis within 28 days of randomization.
- •prothrombin gene mutation 20210, homozygous Factor V Leiden mutations, antiphospholipid syndrome, or a deficiency in antithrombin III, protein C, or protein S.
- •7. History of hypersensitivity to blood, plasma or IVIG excipients.
- •8. Known IgA deficiency or anti-IgA antibodies.
- •9. Medical conditions for which receipt of a 300 mL volume of IV fluid from study treatment may pose specific risk to the patient (e.g., decompensated congestive heart failure).
- •10. In the opinion of the investigator, any condition for which participation would not be in the best interest of the participant or that could prevent or confound protocol assessments.
研究者
相似试验
进行中（未招募）
1 期
Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC)EUCTR2020-002542-16-GBOffice of Sponsored Projects, Regents of the University of Minnesota500
进行中（未招募）
1 期
Same as aboveSubjects infected with SARS-CoV-2, admitted to hospital due to COVID-19MedDRA version: 20.0Level: HLTClassification code 10022005Term: Influenza viral infectionsSystem Organ Class: 100000004862EUCTR2020-002542-16-DERegents of the University of Minnesota500
进行中（未招募）
1 期
Same as aboveSubjects recently tested positive for SARS-CoV-2 infectionMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-001663-24-DKRegents of the University of Minnesota820
尚未招募
2 期
The use of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin in patients with COVID 19 - a trial to know its efficacy and safetyCTRI/2021/12/038622niversity of Minnesota500
进行中（未招募）
1 期
Same as aboveEUCTR2020-002542-16-DKRegents of the University of Minnesota500